scispace - formally typeset
Open AccessJournal ArticleDOI

Targeting CDK4/6 in patients with cancer

Reads0
Chats0
TLDR
Current preclinical and clinical data for three selective CDK4/6 inhibitors have been described and the combination of these novel agents with endocrine therapy, such as palbociclib's recent first-line approval in combination with letrozole, is expected to transform the treatment of HR+ breast cancer.
About
This article is published in Cancer Treatment Reviews.The article was published on 2016-04-01 and is currently open access. It has received 316 citations till now. The article focuses on the topics: Palbociclib & Cancer.

read more

Citations
More filters
Journal ArticleDOI

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Journal ArticleDOI

The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

TL;DR: Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers.
Journal ArticleDOI

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

TL;DR: This review summarizes the currently available knowledge regarding mechanisms of resistance to CDK4/6 inhibitors, and possible therapeutic strategies that may overcome this resistance as well.
Journal ArticleDOI

Exploiting senescence for the treatment of cancer

TL;DR: In this article , the authors discuss how senescence can be induced in cancer cells and how distinctive features of senescent cancer cells might be exploited for their selective eradication as a potential cancer therapy.
References
More filters
Journal ArticleDOI

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 - 
TL;DR: The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Journal ArticleDOI

Cell cycle, CDKs and cancer: a changing paradigm

TL;DR: Genetic evidence suggests that tumour cells may also require specific interphase CDKs for proliferation, and selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.
Related Papers (5)